Narasimhan attributed the raised full-year earnings guidance to strong key brands, new launches and efficiency gains.
Novartis CEO Vas Narasimhan said that the strong performance of key brands and newly launched products, together with measures to improve manufacturing efficiency, supported the company's decision to raise its full-year earnings outlook.Original (zh)
诺华首席执行官万思瀚（Vas Narasimhan）表示，重点品牌及新上市产品的强劲表现，加上生产效率提升措施，为公司上调全年盈利预期提供了支持。
All statements by Vas Narasimhan ›
Narasimhan recalled that being named Novartis CEO at around age 40 had seemed implausible to him at the time.
It didn’t seem plausible, at the time I was only 40.
Novartis CEO Vas Narasimhan said Q3 was the first quarter in which he saw AI genuinely improve the company's financial results, though the contribution was not quantified.
This is the first quarter where I truly see AI beginning to actually improve our financial results.Original (zh)
這是我真正看到AI開始確實改善我們財報的第一個季度。
Narasimhan said Novartis expects to return to dynamic growth in 2027 after a rough quarter of pipeline setbacks.
We do expect to get back to where we were, dynamic growth, in 2027,
Narasimhan explained that the $1.9 billion write-off on the Avidity deal stemmed from delayed timelines and additional clinical work needed for del-desiran.
primarily driven by the time line shifting out” and “the additional clinical work that needs to be completed,
Narasimhan said Novartis' priority brands kept performing well in Q3, led by Kisqali, Kesimpta, Scemblix, Leqvio and Rhapsido.
"Priority brands continued to perform well in the quarter," Narasimhan said, citing growth across Kisqali, Kesimpta, Scemblix, Leqvio and Rhapsido.